ライフサイエンスコーパス: patent

1 ging from zero (total occlusion) to 8 (fully patent).

2 arch articles (80%) link forward to a future patent.

3 d, leaving the large vessels of the fibroids patent.

4 ral ossification, while other sutures remain patent.

5 intervening penetrating vessels were acutely patent.

6 s, indicating that the periplasmic cavity is patent.

7 a grant and its propensity to be cited by a patent.

8 s well as so-called prophetic compounds from patents.

9 d disposition data and bioactivity data from patents.

10 impact publications, and 14% fewer follow-on patents.

11 Office may hear new challenges to stem cell patents.

12 wondered how genes were ever the subjects of patents.

13 he data are gathered from the literature and patents.

14 rate articles that are subsequently cited by patents.

15 n lymph node biopsies of follicular lymphoma patents.

16 ased on information in scientific papers and patents.

17 to control blood glucose levels in diabetic patents.

18 om scientific articles and, increasingly, US patents.

19 Food and Drug Administration approval and by patents.

20 action roles and yields, from pharmaceutical patents.

21 erformed within 3 months of diagnosis in 561 patents.

22 st time, that isolated human genes cannot be patented.

23 n public research investments and subsequent patenting.

24 Eligible patients from the PATENT-1 study entered the PATENT-2 open-label extension

25 patients from the PATENT-1 study entered the PATENT-2 open-label extension, which will continue until

26 rial hypertension receiving riociguat in the PATENT-2 study.

27 396 patients entered PATENT-2, of whom 197 patients were receiving riociguat

28 efficacy data from the final data cutoff of PATENT-2, where most patients had received at least 2 ye

29 Riociguat was well tolerated in PATENT-2.

30 eal-world networks, including 3.7 million US patents, 575,000 physics articles from the arXiv preprin

31 Similarly, most patents (61%) link backward to a prior research article.

32 n level variables (contagious disease rates, patenting activity, economic productivity and crime) wit

33 ary circulation observed at surgery remained patent after plication.

34 usculature maintaining the architecture of a patent airway conduit and abdominal wall and internal in

35 -inflation upon surfacing, while maintaining patent airways.

36 These patents, along with other biological patents, generated

37 nimals survive the 14-day study period, with patent and functional grafts, and gain significantly mor

38 progression rates were then compared between patent and occluded vessels for each vessel type with Fi

39 nstrates the utility of publically available patent and publication data to quantify innovations with

40 hy-Smith America Invents Act (AIA), the U.S. Patent and Trademark Office may hear new challenges to s

41 substantial and fruitful connections between patenting and prior scientific inquiry.

42 The initial search retrieved 52,046 patents and 1,801,075 publications.

43 We study 4.8 million U.S. patents and 32 million research articles to determine th

44 towards the daily use, analysing the various patents and applications reported to date.

45 st prices are issues of regulatory approval, patents and intellectual property, assessment of value a

46 ary text input (e.g. scholarly publications, patents and medical records) in multiple formats (e.g. B

47 Patents and publications (1981-2011) were evaluated usin

48 is study were to assess the applicability of patents and publications as metrics of surgical technolo

49 enzyme immobilization have been described in patents and publications, relatively few processes emplo

50 evaluate the historical relationship between patents and publications; develop a methodology that can

51 sment study based mainly on information from patents and scientific articles, enabling prospective li

52 ly multiplying number of research papers and patents and the broadening range of chemical, medical, e

53 Our analysis uses 1.8 million US patents and their citation properties to map the innovat

54 All BVS were widely patent, and binary restenosis rate was 2% (the only rest

55 the history of tenure in the United States, patents, and licensing at universities, the current stat

56 ions, there is a steady increase in costs of patented anticancer agents over time.

57 tococcal meningitis relies on three old, off-patent antifungal drugs: amphotericin B deoxycholate, fl

58 the IMA ostium and the number of additional patent aortic side branches are associated with the deve

59 IMA type II endoleak had significantly more patent aortic side branches before EVAR than did patient

60 the IMA ostium, and the number of additional patent aortic side branches from the aneurysm sac.

61 s, the bulk of the effect of NIH research on patenting appears to be indirect.

62 s described in the primary literature and in patent applications.

63 e, open and timely set of annotated compound-patent associations, complemented with sophisticated com

64 bleeding was reported and the shunt remained patent at a 3-year follow-up.

65 is a pressing need shared by researchers and patent attorneys from different chemical disciplines.

66 label propagation such as labeling blogs and patents based on their citation networks.

67 35%), antibiotics (46%), chlorhexidine (8%), patent blue dye (8%) and others (8%).

68 Tumor perfusion was assessed by Patent blue staining.

69 ne (E127), Red 2G (E128), Allura Red (E129), Patent Blue V (E131), Indigo Carmine (E132), Brilliant B

70 ully patent, minimal, or no reflux; (b) >50% patent but some reflux; (c) some patency but >50% reflux

71 ferent reaction types used in pharmaceutical patents but a trend toward lower median yield for some o

72 Although policy-makers often focus on direct patenting by academic scientists, the bulk of the effect

73 All cases had a patent canalicular system as demonstrated by syringing a

74 n = 10) required a Lester-Jones tube despite patent canaliculi, with a success rate of 90%.

75 analostomy would induce apical flow from the patent cochlear aqueduct to the canalostomy due to influ

76 rgeon" OR "surgical" OR "surgery." Resulting patent codes were grouped into technology clusters.

77 No association between patent collateral circulation and favorable outcome was

78 ngi establish NSC319726 as a repurposed, off-patent compound that has potential antifungal activity.

79 tional cardiologist then measured FFR in all patent coronary arteries of stentable diameter (>/=2.25

80 In addition, publication and patent counts were closely correlated in areas of techno

81 l US performed three weeks later confirmed a patent covered stent and complete aneurysmal exclusion.

82 procedure, showed an excluded aneurysm and a patent covered stent.

83 BMP10 that correlated with the presence of a patent DA.

84 ormation from different sources (literature, patent databases) and novel sequence data to identify un

85 Electronic patenting databases and the MEDLINE database were search

86 The US share of life science patents declined from 57% (1981) to 51% (2011), as did t

87 find that about 10% of NIH grants generate a patent directly but 30% generate articles that are subse

88 t cases, and discuss the future of stem cell patent disputes.

89 bilities against the compound repository and patent document corpus; given the wealth of knowledge hi

90 pus; given the wealth of knowledge hidden in patent documents, analysis of SureChEMBL data has immedi

91 rom the full text, images and attachments of patent documents.

92 million compounds extracted from 14 million patent documents.

93 nctionalization for the rapid synthesis of a patented drug candidate.

94 or AML, we screened a library of on- and off-patent drugs and identified the antimalarial agent meflo

95 ts of drug research, including resources for patented drugs, their side effects, withdrawn drugs, and

96 7, 47%), atrial septal defects (20/47, 43%), patent ductus arteriosus (16/47, 34%), persistent left s

97 ds ratio [AOR], 0.81; 95% CI, 0.67-0.98) and patent ductus arteriosus (AOR, 0.74; 95% CI, 0.62-0.89).

98 consensus for the screening and treatment of patent ductus arteriosus (PDA) in extremely preterm infa

99 Nonsyndromic patent ductus arteriosus (PDA) is a common congenital he

100 Patent ductus arteriosus (PDA) is associated with increa

101 Observational studies have associated patent ductus arteriosus (PDA) ligation among preterm in

102 Patent ductus arteriosus (PDA) poses a diagnostic and th

103 od flow may undergo palliation with either a patent ductus arteriosus (PDA) stent or a modified Blalo

104 Only one atrial septal defect (ASD) and two patent ductus arteriosus (PDA) were missed by DSCT.

105 ve (BAV), coarctation of the aorta (CoA) and patent ductus arteriosus (PDA).

106 trial septal defect (ASD); device closure of patent ductus arteriosus (PDA); pulmonary valvuloplasty;

107 tal defect (aORs ranging from 1.29 to 2.17), patent ductus arteriosus [aORs = 1.54, 1.63; 95% confide

108 Patent ductus arteriosus and coarctation of aorta occurr

109 11 (c.4599+1delG) was identified in familial patent ductus arteriosus and found to disrupt normal spl

110 Patent ductus arteriosus ligation among preterm neonates

111 tricular leukomalacia, chronic lung disease, patent ductus arteriosus requiring surgery, retinopathy

112 treated cases regardless of whether preterm patent ductus arteriosus was included.

113 f infants who required surgical closure of a patent ductus arteriosus was lower in the budesonide gro

114 al CHD, 4 with atrial septal defects, 2 with patent ductus arteriosus, 2 with tetralogy of Fallot, an

115 A concomitant cardiac lesion, for example, patent ductus arteriosus, and aortic cross-clamp time we

116 facial dysmorphology, osteochondrodysplasia, patent ductus arteriosus, cardiomegaly, pericardial effu

117 cts, persistent left superior vena cava, and patent ductus arteriosus, were present in 32% of patient

118 s of death or bronchopulmonary dysplasia and patent ductus arteriosus.

119 unts, H-type portal-caval, portohepatic, and patent ductus venosus patients had a successful 1-stage

120 to include or exclude all types of DNA from patent eligibility could impact future incentives for ge

121 FFR was measured in all major patent epicardial coronary arteries with a visual stenos

122 -33) months, all venous reconstructions were patent except for 1 tubular graft (97%).

123 ding on third-party payer issues and product patent expiration dates.

124 ding on third-party payer issues and product patent expiration dates.

125 g reduced efficiency, stagnant success rate, patent expirations for key drugs, fierce price competiti

126 educed efficiency, declining innovation, key patent expirations, fierce price competition from generi

127 These are associated with not only expanding patent extraction but also increasingly large vendor col

128 were 18 to 40 years of age, had at least one patent fallopian tube and a normal uterine cavity, and h

129 omen 18 to 40 years of age with at least one patent fallopian tube were randomly assigned to ovarian

130 of it in Anglo and European regions, whereas patents' families/friends were the most common source in

131 fusion had no effect on the EPR in rats with patent femoral arteries (n = 9).

132 infusion on the pressor reflex in rats with patent femoral arteries.

133 Immune modulation is a hallmark of patent filarial infection, including suppression of anti

134 the new law affects challenges to stem cell patents, focusing on two recent cases, and discuss the f

135 the course of in vitro culture and remained patent for 3 days after orthotopic transplantation in ra

136 ld-type controls, and their sutures remained patent for a longer period of time.

137 ovenous shunts and implanted in pigs, remain patent for at least 8 h without anticoagulation.

138 potential anticancer drug tranilast has been patented for treating Alzheimer's disease (AD), in which

139 n of oxetane derivatives appearing in recent patents for medicinal chemistry applications.

140 The patents for the first approved treatments for relapsing-

141 ned patients 18 to 60 years of age who had a patent foramen ovale (PFO) and had had a cryptogenic isc

142 dary prevention of embolism in patients with patent foramen ovale (PFO) and otherwise unexplained isc

143 Patent foramen ovale (PFO) can be detected in up to 43%

144 Trials of patent foramen ovale (PFO) closure to prevent recurrent

145 Patent foramen ovale (PFO) has been associated with migr

146 The efficacy of closure of a patent foramen ovale (PFO) in the prevention of recurren

147 Patent foramen ovale (PFO) is associated with cryptogeni

148 A patent foramen ovale (PFO) may permit arterial embolizat

149 ive effectiveness of percutaneous closure of patent foramen ovale (PFO) plus medical therapy versus m

150 o right-to-left shunted blood flow through a patent foramen ovale (PFO) would not be cooled.

151 udy was to evaluate the relationship between patent foramen ovale (PFO), ischemic stroke, and subclin

152 Patients with a patent foramen ovale and ischemic stroke, transient isch

153 ion of cryptogenic embolism in patients with patent foramen ovale are administration of antithromboti

154 Initial results using these tools to perform patent foramen ovale closure are described.

155 As a demonstration of both technologies, patent foramen ovale creation and closure was performed

156 Closure of a patent foramen ovale for secondary prevention of cryptog

157 ificant benefit associated with closure of a patent foramen ovale in adults who had had a cryptogenic

158 Whether closure of a patent foramen ovale is effective in the prevention of r

159 rocedure (11%), aortic valve procedure (9%), patent foramen ovale or atrial septal defect closure (23

160 Whether closure of a patent foramen ovale reduces the risk of recurrence of i

161 In the second group, the patent foramen ovale was not successfully created in 1 a

162 randomly assigned to undergo closure of the patent foramen ovale with the Amplatzer PFO Occluder or

163 occurred in 47% (including 17% with isolated patent foramen ovale), and 11% had undetermined stroke e

164 uding occult paroxysmal atrial fibrillation, patent foramen ovale, aortic arch atherosclerosis, atria

165 When pulmonary embolism coexists with a patent foramen ovale, increased pressure in the right at

166 , to medical therapy alone or closure of the patent foramen ovale.

167 c medications or percutaneous closure of the patent foramen ovale.

168 DVT and paradoxical embolism due to existing patent foramen ovale.

169 All patent foramen ovales were completely closed in the firs

170 opulation, harbor a third of infections with patent gametocytes between May and August, when transmis

171 These patents, along with other biological patents, generated substantial social and political crit

172 eloped during a time when it was possible to patent genes.

173 A survey of the claims of antibody-related patents granted by the European Patent Office and a revi

174 cantly greater in the early ST compared with patent group (28% vs.11%, p < 0.001; 27% vs. 15% p = 0.0

175 n of this preexisting network structure with patent growth in upstream technology fields has strong p

176 All patents had fasting blood tests and anthropometric measu

177 hin the ablation zone (P = .02) but not with patent hepatic (P = .57) or portal (P = .14) veins.

178 ion rates were significantly correlated with patent hepatic arteries within the ablation zone (P = .0

179 t of 8 patients (75%) were asymptomatic with patent hepatic artery, which was confirmed by multislice

180 It requires no antibody and exploits the patented homogeneous time-resolved fluorescence (HTRF) t

181 The RA was found to be patent in 24 cases (84.8% patency).

182 P2 KO arteries grafted into WT mice remained patent in vivo.

183 imately successful campaign to overturn gene patents in court.

184 During early healing, patents in the azithromycin group exhibited a significan

185 The top 10 most-cited patents in the field were dominated by 2 private entitie

186 Patients with ER and patent index artery at 24 hours on CTA were labeled as h

187 h (Wuchereria bancrofti) infection such that patent infection altered the frequency and distribution

188 s highly infectious sporozoites that produce patent infection in mice that are exposed to the bites o

189 e mutant was associated with higher risks of patent infection in peripheral blood (adjusted prevalenc

190 The association of patent infections at enrollment with low birth weight su

191 The tool identified both prepatent and patent infections using Schistosoma japonicum DNA isolat

192 ges in mean monthly costs for a cohort of 24 patented, injectable anticancer drugs that were approved

193 entation of medical research, the process of patenting intellectual property, and its potential impac

194 eyes had ischemic nonfunctioning blebs with patent internal ostia and underwent Nd:YAG LGP, followed

195 ermine the minimum citation distance between patented inventions and prior scientific advances.

196 of preparation, physicochemical properties, patented inventions and recent advances of these micelle

197 ripheral anterior chamber in the presence of patent iridotomy, with intraocular pressure (IOP) of 22

198 Leaving science to pursue a career in patent law requires a considerable investment of time an

199 e number of former scientists now practicing patent law shows that it can be done.

200 earchers (and patent offices) began to apply patent-law logic to genes themselves.

201 frequent in thrombosed lesions compared with patent lesions (70% vs. 43%, p = 0.045) and maximal unde

202 s significantly greater in thrombosed versus patent lesions.

203 to screen and characterize FDA-approved, off-patent library drugs for anti-Mycobacterium tuberculosis

204 sities should expand their criteria to treat patents, licensing, and commercialization activity by fa

205 Using data on patents linked to U.S. National Institutes of Health (NI

206 The data are extracted from the patent literature according to an automated text and ima

207 KDMs, KDM2-7), focusing on the academic and patent literature from 2014 to date.

208 ents for the treatment of IPF along with the patent literature from the past 10 years.

209 a quinoline series recently disclosed in the patent literature into a chemotype previously used for t

210 c modulators disclosed in the scientific and patent literature.

211 cements, with a focus on both scientific and patent literature.

212 ratory, and the other is a compound from the patent literature.

213 gonists and summarizes the peer reviewed and patented literature.

214 these instances have been central issues in patent litigations.

215 h self-expandable metal stents (SEMS) remain patent longer than plastic stents, they are more expensi

216 ccluded, significantly stenosed (>/=50%), or patent (<50% stenosis).

217 ta-catenin at the plasma membrane, induced a patent lumen in CRC spheroids, and slowed CRC cell invas

218 and stabilization of endothelial tubes with patent lumens is vital during vertebrate development.

219 stal extension of both the apical border and patent lumens.

220 Approximately 256 traditional Chinese patent medicines, containing Aristolochiaceous materials

221 were performed for relevant clinical trials, patents, meeting abstracts, and awards of NIH funding.

222 NAs) with potential utility as biomarkers of patent (mf (+) ) L. loa infection.

223 rimal syringing and categorized as (a) fully patent, minimal, or no reflux; (b) >50% patent but some

224 n-Friendly (GF) technology (Italian priority patent n degrees 102015000084813 filed on 17th December

225 mors we noted the emergence of CD31-negative patent neovessels and a concomitant loss of tumor homing

226 try level: the global trade network, and the patent network in different technological domains.

227 stration of numerous cell types and leads to patent, nonleaky, properly organized, and functional nas

228 tool extracting strain related publications, patents, nucleotide sequences and genome information fro

229 Once the patent of a brand-name drug expires, generic drugs are c

230 n, CTDs, and their derived dioxins since the patent of triclosan in 1964.

231 ived from triclosan are present prior to the patent of triclosan, suggesting a secondary source.

232 body-related patents granted by the European Patent Office and a review of the type and scope of prod

233 sequence came to fruition, researchers (and patent offices) began to apply patent-law logic to genes

234 ad evidence of a patent ostium and 100% were patent on lacrimal irrigation.

235 Myriad Genetics, a company with patents on BRCA1 and BRCA2, two genes critical to assess

236 ogy v Myriad Genetics, Inc seeks to overturn patents on isolated genes.

237 ity and the University of California to seek patents on the technology that Boyer and I had invented,

238 ility and outcomes of retrograde CTO PCI via patent or occluded saphenous vein graft.

239 ly, all coronary bypass grafts were rated as patent or occluded.

240 n within a cohort of commonly prescribed off-patent oral antibiotics.

241 This inexpensive and off-patent oral medication is a promising adjunctive antifun

242 89% of the cases (n = 58) had evidence of a patent ostium and 100% were patent on lacrimal irrigatio

243 es, 127 (98.5%) had endoscopic evidence of a patent ostium with a positive endoscopic dye test at the

244 new data to track publication, citation, and patenting outcomes associated with more than 130,000 res

245 reactions and molecules retrieved from U.S. patents over the past 40 years (1976-2015).

246 preterm labour was also more common in these patents (p < 0.05).

247 Yet, advances directly along the patent-paper boundary are notably more impactful within

248 ; pharmacological properties of published or patented PAR2 modulators (small molecule agonists and an

249 with PfUIS3 can induce a consistent delay in patent parasitemia across mouse strains and against chim

250 s in hydronephrosis and failure to develop a patent pelvic-ureteric junction.

251 trochemical continuous enzyme assay (ICECEA, patent pending) was developed for the fast determination

252 During the patent phase of Schistosoma mansoni infection, Foxp3(+)

253 ew innovation bonds, administrative savings, patent pools, and public-private risk sharing collaborat

254 At all time points, the struts along the patent portions of the aneurysm necks harbored scattered

255 occlusion or stenosis and the presence of a patent portosystemic shunt.

256 Researchers can participate in the patent process without sacrificing a robust publishing c

257 mbined with a basic understanding of how the patent process works.

258 nticancer drugs ("chemotherapies") that were patent protected and administered intravenously to patie

259 Patent protection for several LMWH has expired and abbre

260 K9i drug price of $14300, with a lapse in US patent protection that would reduce the price by 43% in

261 Drawing on millions of papers and patents published over 30 years, we use this model to in

262 nvoluntary acquisition of the pharmaceutical patents pursuant to federal statutory authority and prin

263 The overall survival time of completely patent PV and incomplete patent PV immediately after TIP

264 time of completely patent PV and incomplete patent PV immediately after TIPS was 57.05 +/- 0.75 vs.

265 omosis was performed in 4 cases of small but patent PV.

266 tion (LRVL) is another option but requires a patent PV.

267 ribute to onward transmission and subsequent patent recrudescence.

268 search, from both scientific literatures and patents, related to the compaction of TMUPS.

269 The unprecedented weakening of patent rights in the United States undermines necessary

270 riptional signature of TET2 mutations in MPN patent samples.

271 Fewer patent secondary follicles were isolated from treated ov

272 Exemplars from a patented series of GPR84 antagonists were able to block

273 ese include reverse payment or pay-for-delay patent settlements, authorized generics, product hopping

274 S. mansoni egg-induced pathology during the patent stage of infection.

275 d documented long-term clinical success with patent stents and no symptoms at one year following inte

276 nce, more particularly CHEMDNER and CHEMDNER patents tasks of BioCreative IV and V, respectively.

277 ormation contained in scientific literature, patents, technical reports, or the web is a pressing nee

278 tically, and show that 'complex' products or patents tend often to be those that countries rarely pro

279 the Bxb1-att nor the Cre-lox system is under patent, there is freedom to operate.

280 as well as SureChEMBL for recent PDE related patents, to provide a wider context for exploring fragme

281 eyes with ischemic nonfunctioning blebs and patent trabeculectomy ostia.

282 Here, we compare the outcome of patents treated within the Veterans Health Administratio

283 Linked papers and patents typically stand 2 to 4 degrees distant from the

284 "products of nature" were not eligible to be patented unless they were "isolated and purified" from t

285 tion coexisted with other anomalies, such as patent urachus, Meckel's diverticulum, mesenteric cyst,

286 impact on new drug development, as new drug patents usually involve cellular methods.

287 Follow-up ultrasound demonstrated patent vasculature without evidence of thrombosis or out

288 ion is suppressed and maintains a quiescent, patent vasculature.

289 rmed 24 hours after the procedure revealed a patent vessel with satisfactory blood flow.

290 Imaging demonstrated patent vessels with only mild luminal narrowing/occlusio

291 he ablation zone, largely along persistently patent vessels.

292 ad a history of liver toxic drug absorption, patent viral infection, or any histopathological finding

293 The excluded aneurysm sac shrank with patent visceral branches and there was an absence of end

294 Isolated DNA patents were already becoming obsolete on scientific gro

295 logical assessment, revealed both BRSs to be patent with nonobstructive neointimal hyperplasia.

296 culprit vessel may be preserved in selected patents with NSTEMI.

297 ization is essential to optimize outcomes in patents with ST-segment-elevation myocardial infarction

298 in K antagonist (VKA) in atrial fibrillation patents with stable coronary artery disease.

299 raphy at 1 month showed that all shunts were patent, with no thrombosis or migration.

300 609 (26.7%), of which 150 (92%) occurred in patents without antecedent CMV viremia.